Jim Long Joins Notal Vision as Chief Financial Officer

Former Managing Director for Empresario Partners and Interim CFO for MDLive

Life Science Partner has recruited Jim Long to serve as Notal Vision’s Chief Financial Officer. Notal Vision is a health technology company offering the first patient-activated, home-based monitoring system to prevent the progression of macular degeneration through early detection and intervention. As the CFO of Notal Vision, Long will report to Quinton Oswald, CEO, and will be responsible for overseeing all financial matters including fundraising to accelerate the company’s growth trajectory.

Long has extensive tenure in leading healthcare companies’ financial planning and operations along with notable successes in creating strategic partnerships for realigned the financial team culture and performance while partnering with the Board Chairs, Founders, and Senior Executives to bring key initiatives to fruition.  His financial leadership of several major company transitions is regarded as a key asset for his new role at Notal Vision.

“Having led multiple corporate sales requiring post-sale restructuring as the head financial officer, Long has the background in complex financing required to fund Notal Vision’s aggressive growth objectives,” states Tom Callaway, MD, President and Founding Partner of Life Science Partner.  “He will be an excellent partner with Quinton to build a highly valuable company.”

Long earned his Bachelor of Arts Degree in Economics and Spanish and his MBA in Finance and Accounting from The University of Texas at Austin.

 

Roni Amiel Joins Notal Vision as Chief Information Officer

Former Chief Information Officer, Pinscriptive

Life Science Partner has recruited Roni Amiel to serve as Notal Vision’s Chief Information Officer. Notal Vision is a health technology company offering the first patient-activated, home-based monitoring system to prevent the progression of macular degeneration through early detection and intervention.  In this new role, Amiel will lead the company’s health innovation technologies strategy, development, and implementation.

Amiel is well qualified for this innovative company’s leadership. As Co-Founder and CIO of Pinscriptive, Amiel built the company’s technology platform from the ground up integrating with payers, providers, and pharmaceutical companies.

Previously, Amiel served as the CIO for Blythedale Children’s Hospital where he led the implementation of enterprise information systems and technical services. Earlier in his career Amiel served in IT leadership roles for the City of New York’s Department of Health, Columbia University Medical Center’s Cardiovascular Research Foundation, and PTC Therapeutics. Amiel’s service in the Israeli Navy is an additional asset given Notal Vision’s R&D and production operations in Tel Aviv, as well as its Israeli investor base.

“Amiel is an entrepreneur at heart, with the information technology track record of building tools that improve patients’ lives,” states Tom Callaway, MD, President and Founding Partner at Life Science Partner. “He’ll thrive working with our client Quinton Oswald to build a first-to-market innovative solution to preserve the eyesight of patients with macular degeneration.”

Amiel earned his BS in Information Technology from Colorado Technical University and completed his MBA from Rutgers University.

Bert Slade, MD, Joins Tissue Tech as VP, Clinical Development

Former Chief Scientific and Medical Officer Advanced Wound Care, Smith & Nephew

Life Science Partner recruited Bert Slade, MD, to serve as the Vice President, Clinical Development for TissueTech.  Slade has built his career in leading clinical trials, medical affairs, and regulatory approvals for medical device and pharmaceutical companies worldwide.  He joins TissueTech while also providing clinical support for Chisholm Clinical Research Services where he has set up his own vehicle to conduct clinical trials using the European platform as an inroad to EU product approvals.

During his tenure at Smith and Nephew, Slade was challenged as the first CMO for the Advanced Wound Management Division to restructure the three-strategic business unit R&D Departments and two clinical groups into a single international R&D organization with the addition of post-marketing surveillance.

“With his extensive experience in FDA submissions of BLAs and NDAs including a clinical background in wound healing and regenerative medicine, Slade will serve as a critical asset for TissueTech’s clinical trial designs and submissions,” states Tom Callaway, President and Founding Partner of Life Science Partner.

Slade earned his Bachelor of Arts Degree in Biology from Hamilton College.  He earned his MD from the Upstate Medical Center at the University of New York.

Dave Driscoll Joins Avizia as Senior Vice President, Sales

Sales Leader at Visicue, Medsphere, Conifer Health, GE Centrocity, and Connecture

Life Science Partner has recruited Dave Driscoll to serve as Senior Vice President, Sales for Avizia. Avizia is an innovative telemedicine company providing an end-to-end telehealth platform that integrates care coordination software with industry-leading video devices and mobile apps, enabling clinics and hospitals to deliver quality patient care anywhere. In this new role, Driscoll will lead the expansion of Avizia’s sales program and executing strategies for the company’s continued growth.

As a seasoned sales leader with more than 25 years of experience driving significant top-line growth for multiple companies across the digital healthcare ecosystem, Driscoll is well-equipped to lead Avizia’s sales organization. Driscoll has a solid track record of leading solution-focused sales teams at enterprise software companies such as Visicu, Medsphere Systems, Conifer Health and GE Centricity.

“With and a wide network of strong relationships with integrated delivery networks, Driscoll will play an instrumental role in accelerating Avizia’s growth,” states Tom Callaway, MD, President and Founding Partner of Life Science Partner. “Avizia is the leader in the transformation of telemedicine, particularly in the new world of Accountable Care Organizations that need to link their primary care physicians and specialists.”

Driscoll earned his Bachelor of Business administration from Pennsylvania State University.

Brigham Briggs Joins Smiths Medical as VP, Global Sales Operations

Former Director, Global Sales Operations at Terumo BCT

Brigham Briggs has joined Smiths Medical as Vice President, Global Sales Operations – a newly created role for the company where Briggs will have responsibility over the sales organization worldwide. He will oversee the standardization of the sales pipeline, funnel management and incentive compensation across Smiths Medical’s sites around the globe.

Smiths Medical is a global manufacturer of specialty medical devices that provides innovative and lifesaving solutions for the hospital, emergency, home and specialist environments.

Briggs is well-equipped to lead Smiths’ sales operations after directing the worldwide sales operations, sales excellence, and Customer Centric Initiative for Terumo BCT, a medical device equipment manufacturer focused on blood processing technologies. Earlier, Briggs served as Executive Director, Commercial Operations for GreatBatch Medical where he led a global sales team driving business development, customer support, and revenue growth.

Earlier in his sales career Briggs served in sales leadership roles at American Medical System and Boston Scientific. Before joining the medical device industry, Briggs was a Captain for the US Air Force for Aircraft Maintenance and Logistics.

Briggs earned his Bachelor of Science Degree in Engineering from the United States Air Force Academy. He completed his Master of Science Degree in Logistics Management from the Air Force Institute of Technology and is Six Sigma Black Belt Certified.

Rachael Fleurence, PhD, Joins MDIC as Executive Director, Coordinating Center

Life Science Partner recruited Rachael Fleurence, PhD, to serve as the MDIC’s Executive Director, Coordinating Center in partnership with the National Evaluation System for Health Technology (NEST).

MDIC is the first-ever public-private partnership (PPP) created with the sole objective of advancing medical device regulatory science. MDIC is a nonprofit 501(c)3 organization that operates in partnership with the FDA to improve the medical technology environment. The U.S. Food and Drug Administration (FDA) has awarded the MDIC $3 million in seed funding to establish the Coordinating Center for the Medical Device National Evaluation System for health Technology (NEST).

While at PCORI, Fleurence lead the launch of PCORnet, a national patient centered research network consisting of 130 institutions and patient groups nationwide. She also directed the Clinical Research Methods program in areas including comparative effectiveness research, methods for patient engagement and research prioritization and analytical methodologies.

“The initial phase of the NEST project will include demonstration projects piloting methods for tracking medical device data and patient-reported outcomes through the use of real-world evidence., Fleurence has the unique capability to lead the vision and execution of the MDIC’s Coordinating Center in partnership with NEST,” states Tom Callaway, MD, Founder of Life Science Partner.

Rachael Fleurence earned her Bachelor of Arts Degree in Social and Political Science from University of Cambridge, UK, and her MA in business management from ESSEC- Paris. She completed her Master of Science and PhD in health economics from the University of York. She also completed her AMIA 10X10 Bioinformatics Certificate from the Oregon Health and Sciences University.

Chris Stein, MD, PhD, Joins Allergan As Director, Medical Safety Physician

Former Global Pharmacovigilance and Clinical Safety Physician Otsuka Pharmaceuticals

Chris Stein, MD, PhD, was recruited by Life Science Partner to serve as Director, Medical Safety Physician for Allergan where he will oversee Pharmacovigilance for Allergan’s CNS drug portfolio.

In his previous role at Otsuka, Stein partnered with safety physicians at Bristol Myers Squibb to co-market the block buster drug, Abilify, and formulate a regulatory compliance strategy and risk management plan while providing signal evaluation and drug safety reporting.

“Intelligent, articulate and passionate about pharmacovigilance, Stein will be able to hit the ground running in his CNS role for Allergan’s pharmacovigilance team,” states Tom Callaway, MD, Founder and President of Life Science Partner. “He brings exceptional analytical and writing skills to be a great addition to the team.”

Chris Stein earned his Bachelor of Science Degree in Biology and Computer Science in 1984 from the Southwest Missouri State University. He completed his MD and PhD from the St. Louis University School of Medicine and his MPH from the University of Kentucky College of Public Health.

Tony Brennan Joins UL as Director, North American Sales

Former Director, Business Development at Erdman

Tony Brennan has joined Underwriters Laboratories as Director, North American Sales for the company’s Health Sciences business unit reporting to Upayan SenGupta, Vice President, General Manager, Health Sciences—SenGupta was recruited to UL by Life Science Partner in 2015. Brennan previously served as Director, Business Development for Erdman, a consulting firm dedicated to providing integrated solutions for healthcare clients.

Brennan’s career has been focused on building and leading strategic healthcare sales teams and cultivating key relationships with Group Purchasing Organizations and Integrated Delivery Networks. He has previously held sales leadership roles at HeartSine Technologies, Angelica, Cardionow, Cordis and GE Healthcare.

In his role at UL, Brennan will oversee the sales and new business development for the company’s rapidly growing Health Sciences Division. Brennan will be lead the transformation of the business from selling traditional compliance and audit services to becoming a proactive partner in the registration and product development teams for UL’s clients.

Brennan earned his Bachelor of Science in Biology and Chemistry from Bowling Green State University.

 

Scott Cohn Joins Surgical Specialties as Vice President, Global Quality Assurance

Former Senior Director, Global Quality Assurance Haemonetics Corporation

Scott Cohn was recruited by Life Science Partner to serve as Surgical Specialties’ Vice President, Global Quality Assurance where he will build a quality systems team and implement the harmonization of Surgical Specialties’ quality operations across its manufacturing facilities worldwide.

Cohn joins Surgical Specialties after serving as Senior Director, Global Quality Assurance for Haemonetics Corporation where he led the company’s initiative to improve and drive quality standards to the next level from their global contract manufacturers and suppliers.

As a hands-on leader, Cohn played a key role during Haemonetics acquisition of Pall Medical as he led the stabilization and integration activities to synchronize quality systems and operations for maximum efficiency and quality measures.

“As a results-driven quality management expert with a track record for bringing underperforming plants up to international standards, Cohn will be an essential change-agent leader for Surgical Specialties’ manufacturing operations,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Scott Cohn earned his Bachelor of Science Degree in Business Management in 1991 from Southern Connecticut State University in New Haven.

Jing Xie, PhD, MS, Joins MDIC as Vice President, Clinical Affairs

Former Vice President, Global Clinical Affairs, Zimmer Biomet

Life Science Partner recruited Jing Xie, PhD, MS, former Vice President, Global Clinical Affairs for Zimmer Biomet to become the Medical Device Innovation Consortium’s (MDIC) first Vice President, Clinical Affairs.

MDIC is the first-ever public-private partnership (PPP) created with the sole objective of advancing medical device regulatory science to expedite development, assessment, and review of innovative medical technologies. The overall mission of the MDIC is to support the FDA’s vision to achieve first in the world patient access in the US and to assure the safety and effectiveness of medical devices through the Total Product Life Cycle.

Xie takes on her new role at the MDIC after having oversight of approximatively 300 clinical projects worldwide for Zimmer Biomet. She possesses a highly successful track record in the orthopedic industry for delivering on objectives, while maintaining effective collaboration with internal and external stakeholders.

“With a global understanding around clinical trial management including data integration for regulatory agencies across the US, Europe and Asia, Xie is a well-seasoned leader to execute the clinical affairs initiatives at the MDIC,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Jing Xie earned her Bachelor of Science Degree in Analytical Chemistry from Xiamen University in China and completed her PhD in Materials Science from the University of Alabama. She holds an MS in Computer Science from Purdue University and an MS in Chemistry from the University of Alabama.